Target overview
Synonyms
GPC3
Early Watch
GPC3
GPC3 is flagged as early watch based on 1 active trials across 1 sponsors and 1 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 1
Active trials: 1
Recruiting trials: 1
Known assets: 0
Sponsor activity
Competitive footprint
Unique sponsors: 1
Top sponsors: Zymeworks BC .
Tumor types: Hepatocellular Carcinoma | Squamous Cell Non-Small Cell Lung Cancer | Germ Cell Tumor
Patent-density signal summary
Patent layer
Signal count: 1
Recent signals: 0
Top assignees: Genmab
Signal types: diagnostic_or_patient_selection
Scores and labels
Deterministic summary
Clinical crowding: 1/5 (Low)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 0/5 (Low)
Momentum: 2/5 (Watch)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.